IntraBio Overview
- Year Founded
-
2015
- Status
-
Acquired/Merged
- Employees
-
5
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$2B
IntraBio General Information
Description
Developer of novel therapies designed for the treatment of rare and neurodegenerative diseases with high unmet medical needs. The company's technology includes small molecule drugs for lysosomal storage disorders and orphan indications, enabling healthcare providers to offer specialized treatments for patients with life-threatening genetic conditions.
Contact Information
Website
www.intrabio.co.uk(Operating Subsidiary)
Corporate Office
- 201 West 5th Street
- Suite 1100
- Austin, TX 78701
- United States
Corporate Office
- 201 West 5th Street
- Suite 1100
- Austin, TX 78701
- United States
IntraBio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 18-Nov-2026 | $2B | Completed | Generating Revenue | ||
| 4. Later Stage VC | 23-Mar-2024 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series C) | 05-Apr-2023 | Completed | Clinical Trials - Phase 3 | |||
| 2. Later Stage VC | 05-Nov-2020 | $10.3M | $10.3M | Completed | Clinical Trials - Phase 3 | |
| 1. Early Stage VC | 01-Jul-2017 | Completed | Clinical Trials - Phase 3 |
IntraBio Patents
IntraBio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026236588-A2 | Modulation of transcription factor eb activity by n-acetyl leucine to treat disorders | Pending | 09-May-2025 | ||
| US-20260097008-A1 | Acetyl leucine for use in treating niemann-pick disease type c | Pending | 07-Oct-2024 | ||
| WO-2025264957-A2 | Acetyl leucine for treating neurodevelopmental disorders | Pending | 20-Jun-2024 | ||
| WO-2025264957-A3 | Acetyl leucine for treating neurodevelopmental disorders | Pending | 20-Jun-2024 | ||
| AU-2025223718-A1 | Acetyl leucine for treating syngap1-related disorders | Pending | 14-Feb-2024 | A61P21/00 |
IntraBio Signals
IntraBio Former Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Biohealth Innovation | Corporation | Minority | ||
| Oxford Science Enterprises | Venture Capital | Minority |
IntraBio FAQs
-
When was IntraBio founded?
IntraBio was founded in 2015.
-
Where is IntraBio headquartered?
IntraBio is headquartered in Austin, TX.
-
What is the size of IntraBio?
IntraBio has 5 total employees.
-
What industry is IntraBio in?
IntraBio’s primary industry is Drug Discovery.
-
Is IntraBio a private or public company?
IntraBio is a Private company.
-
What is the current valuation of IntraBio?
The current valuation of IntraBio is .
-
What is IntraBio’s current revenue?
The current revenue for IntraBio is .
-
How much funding has IntraBio raised over time?
IntraBio has raised $65.6M.
-
Who are IntraBio’s investors?
Biohealth Innovation and Oxford Science Enterprises have invested in IntraBio.
-
When was IntraBio acquired?
IntraBio was acquired on 18-Nov-2026.
-
Who acquired IntraBio?
IntraBio was acquired by Shionogi.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process